Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Tax Provisions (2016 - 2025)

United Therapeutics (UTHR) has disclosed Tax Provisions for 17 consecutive years, with $79.7 million as the latest value for Q4 2025.

  • Quarterly Tax Provisions fell 16.28% to $79.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $379.2 million through Dec 2025, up 10.26% year-over-year, with the annual reading at $379.2 million for FY2025, 10.26% up from the prior year.
  • Tax Provisions hit $79.7 million in Q4 2025 for United Therapeutics, down from $99.3 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $101.3 million in Q1 2025 to a low of $4.2 million in Q1 2021.
  • Historically, Tax Provisions has averaged $67.7 million across 5 years, with a median of $76.6 million in 2023.
  • Biggest five-year swings in Tax Provisions: plummeted 87.61% in 2021 and later skyrocketed 1538.1% in 2022.
  • Year by year, Tax Provisions stood at $28.3 million in 2021, then soared by 65.02% to $46.7 million in 2022, then soared by 67.67% to $78.3 million in 2023, then increased by 21.58% to $95.2 million in 2024, then dropped by 16.28% to $79.7 million in 2025.
  • Business Quant data shows Tax Provisions for UTHR at $79.7 million in Q4 2025, $99.3 million in Q3 2025, and $98.9 million in Q2 2025.